<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SDU-Denmark_Tour44 skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SDU-Denmark/Tour44</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="BackgroundLayout"><DIV class="top bannerShadow"><DIV class="NavbarContainer"><DIV class="NavbarContainerInner"><DIV class="MenuButton" id="btnWelcome"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark">Welcome</A></DIV><DIV class="MenuButton" id="btnTour"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Interactive wiki-tour</A></DIV><DIV class="MenuButton" id="btnMenu"><A class="MenuButtonLink" href="#" id="btnMenu2">Menu</A><DIV class="menuPopup"><DIV class="menuPopupContent"><DIV class="menuPopupContentInner bannerShadow"><DIV class="menuIntro"><DIV class="warningBox"><P class="menuIntro">
You really should try our <A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">interactive wiki tour</A> instead! 

</P></DIV><P class="menuIntro">
But if you are looking for a specific page - you are in the right place. 
</P><DIV class="menuItems"><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Introduction</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour11">The Team</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour12">Attributions</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour13">Gallery</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour14">Medal Requirements</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour20"> Antibody Issue</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour21">Antibody Production</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour22">Animal Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour23">The Alternative</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour30">PAST</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour31">Two-Hybrid Screening</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour32">System Design</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour33">Business</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour34">Entrepreneurship</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour40">Process</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour41">Complete Journal</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour42">Collaborations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour43">SOPs</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour44">Safety</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour50">Results</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour51">Characterization</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour52">Two-Hybrid System</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour53">Submitted Parts</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour54">Interlab Study</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour60">Practices</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour61">Survey</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour62">Education</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour63">Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour64">A Children's Book</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour70">
What is Next?</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour71">Challenges and Limitations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Medical Aspects</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Lab Work</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour73">The End</A></LI></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV><DIV class="tourBoundingBox"><DIV class="tourBoundingBoxInner bannerShadow"><DIV class="parentTourItem "><A class="tourItemLabel" title="Get a brief overview of the project.">
                Introduction
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="Would you like to meet our team?">
                       The Team
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="To express our thankfulness.">
                        Attributions
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Gallery
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medal Requirements
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               Antibody issue
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Antibody production
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Animal Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        The Alternative
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                PAST            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Two-Hybrid Screening
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        System Design
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Business
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Entrepreneurship
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                Process
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Complete Journal
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Collaborations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       SOPs
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Safety
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">       Results
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Characterization
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      Two-Hybrid System
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Submitted Parts
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Interlab Study
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
Practices
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Survey
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Education
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title=""> A Children’s Book
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               What is Next
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Challenges and Limitations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medical Aspects
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Lab Work
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      The End
                    </A></DIV></DIV></DIV></DIV></DIV><DIV class="MainLayout"><DIV class="content"><P><I> &quot;Safety First” is “Safety Always.&quot; - <B>Charles M. Hayes</B></I></P><H1 align="center">Safety</H1><P> 
Safety for the public, environment and the biologist working in a GMO classified lab is important. When classifying a GMO its pathogenesis and ability to spread from one host to another are the two main focus poin<SPAN class="sourceReference">ts</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
World health organization, third edition, 2004 - Visited: 16.09.15. 
   <A target="_blank" href="http://www.who.int/csr/resources/publications/biosafety/en/Biosafety7.pdf?ua=1 "> [WHO] </A></SPAN></P>

 When added up they imply level of risk for a specific organism. The leveling ranges from 1 to 4, where one implies for an organism that has no pathogenesis towards humans and is unable to  It is important for us a synthetic biologist’s to recognize a level of danger and act accordingly. In Denmark Arbejdstilsyn<SPAN class="sourceReference">et</SPAN><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Arbejdstilsynet - Visited: 16.09.15. 
   <A target="_blank" href="http://arbejdstilsynet.dk/da/regler/at-vejledninger/k/c-0-4-klassifikation-af-laboratorier.aspx "> [Arbejdstilsynet] </A></SPAN>

 overlooks, the laws applying for a synthetic bio-l<SPAN class="sourceReference">ab</SPAN>,
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Lov om miljø og genteknologi - Visited: 16.09.15. 
   <A target="_blank" href="https://www.retsinformation.dk/Forms/R0710.aspx?id=132155 "> [RetsInformation] </A></SPAN>
 and they live up to the criteria that has been set by W<SPAN class="sourceReference">HO</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
World health organization, third edition, 2004 - Visited: 16.09.15. 
   <A target="_blank" href="http://www.who.int/csr/resources/publications/biosafety/en/Biosafety7.pdf?ua=1 "> [WHO] </A></SPAN><P>
To create and test the Two-hybrid system we worked with E.coli K12 strains. When doing assembly mainly E.coli K12 MG1655. Then for testing our constructs E.coli K12 BTH101 was used. Both of this are non-pathogenic strains, MG1655 are categorized as Risk Group 1 having mutations in rpy, ilvG and rfb-50. It lacks colonization factors and is unable produce O antig<SPAN class="sourceReference">en</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
E.coli Genome Project, University of Wisconsin - Visited: 16.09.15. 
   <A target="_blank" href="http://www.genome.wisc.edu/resources/strains.htm "> [Genome] </A>
NIH Guidelines for research involving - Visited: 16.09.15. 
   <A target="_blank" href="http://osp.od.nih.gov/sites/default/files/NIH_Guidelines.html#_Toc351276292 "> [NIH] </A></SPAN>

BTH101 has been optimized for the use of a bacterial two-hybrid system. It is deficient in adenylate cyclase and has a β-galactosidase reporter system incorporated into its geno<SPAN class="sourceReference">me</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
WO 2001073108 A2 - Patent - Visited: 16.09.15. 
   <A target="_blank" href="http://www.google.com/patents/WO2001073108A2?hl=da&amp;cl=en "> [Google.Patents] </A></SPAN>

 BTH101 is like MG1655 in Risk group 1.
List of strains, used in our project;
</P><P>
All our basic bricks arise form risk group 1 E.coli K12 strains. The targets for our peptide aptamers come from E.coli K12 MG1655. The scaffold protein human thioredoxin originate form Homo sapiens, and lacks its catalytic activity.
The peptide aptamer library was synthesized at random therefore, we cannot guarantee one of the millions of possibilities will not be harmful or resemble a toxin. Because of this and according to the European-parliament 2009/41/EF article 4 paragraph 4; we are obligate to take make the highest risk assessme<SPAN class="sourceReference">nt</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
The EU-parliaments directive 2009/41/EF - Visited: 16.09.15. 
   <A target="_blank" href="http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:125:0075:0097:DA:PDF "> [Eur-Lex] </A></SPAN>

However, this assessment must be added up with the risk assessment of the E.coli strain used. Therefore, there is a low risk for the environment and a potential risk for the biologist, this assessment add up to a classification of Risk Group 2 following the Safety rules of the <SPAN class="sourceReference">EU</SPAN>.
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Europa-parlementets og rådets direktiv 2009/41/EF - Visited: 16.09.15. 
   <A target="_blank" href="http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:125:0075:0097:DA:PDF "> [Eur-Lex]
 </A>
Arbejdstilsynet - Visited: 16.09.15. 
   <A target="_blank" href="http://arbejdstilsynet.dk/da/regler/at-vejledninger/k/c-0-4-klassifikation-af-laboratorier.aspx "> [Arbejdstilsynet]
 </A></SPAN></P><P>
As written in the Biosafety management paragraph from W<SPAN class="sourceReference">HO</SPAN><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
World health organization, third edition, 2004 - Visited: 16.09.15. 
   <A target="_blank" href="http://www.who.int/csr/resources/publications/biosafety/en/Biosafety7.pdf?ua=1 "> [WHO] </A></SPAN>

everyone working in a bio-lab must revive proper instructions of how to work with GMO.
In the microbiology department for SDU Medical Laboratory Technician Simon Rose is the laboratory supervisor.
</P></DIV><DIV class="footer "><DIV class="footerContainer"><A class="footerBtn footerShadow" id="btnFastForward"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnNextChapter"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnDigDeeper"><P class="footerBtnPre">Dig deeper
</P></A><A class="footerBtn footerShadow" id="btnTheEnd" href="http://www.igem.org" target="_blank"><P class="footerBtnPre">End of tour
</P><P class="footerBtnHeader" style="text-transform: none !important;">Want more? Go to iGEM.org!</P><P class="footerBtnText">
If you want to learn more about Synthetic Biology you should visit iGEM's homepage, which contains loads on the subject. You can even visit other teams' wikis and take a look at what they accomplished. Or maybe join a team yourself?</P></A></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>